Plus Therapeutics, Inc. (PSTV)

Market Cap	82.22M
Revenue (ttm)	5.26M
Net Income (ttm)	-20.58M
Shares Out	137.43M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,470,603
Open	0.5697
Previous Close	0.5608
Day's Range	0.5671 - 0.6300
52-Week Range	0.1634 - 2.3100
Beta	0.84
Analysts	Strong Buy
Price Target	7.25 (+1,111.77%)
Earnings Date	Oct 30, 2025

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary live...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTV
• Website: https://plustherapeutics.com

Financial Performance

In 2024, Plus Therapeutics's revenue was $5.82 million, an increase of 18.54% compared to the previous year's $4.91 million. Losses were -$12.98 million, -2.54% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price target is $7.25, which is an increase of 1,111.77% from the latest price.

Price Target

$7.25

(1,111.77% upside)

Analyst Consensus: Strong Buy